FDA and EMA ac­cept Pfiz­er’s reg­u­la­to­ry sub­mis­sions for ul­cer­a­tive col­i­tis drug

Pfiz­er’s S1P re­cep­tor mod­u­la­tor for treat­ing ul­cer­a­tive col­i­tis, etrasi­mod, which was at the cen­ter of a bil­lion-dol­lar buy­out from Are­na Phar­ma, has now tak­en …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER